A study comparing ayurvedic herbal decoction (Aaragwadhadi Kashay)and a standard steroid medicine (deflazacort)for the treatment of atopic dermatitis (vicharchika )causing reduction in itching ,oozing

A clinical evaluation of efficacy of Aaragwadhadi kashay in comparision with Deflazacort using EASI scale in Vicharchika with special reference to Atopic Dermatitis :a randomized control trial - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/100205

Enrollment

Registered

2026-01-02

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients with one or more classical symptoms and sign of vicharchika for more than 6 weeks EASI Score 7.1 to 21.0 moderate

Exclusion criteria

Exclusion criteria: Patients with systemic illness, uncontrolled diabetes Patient using corticosteroids or immunosuppressant from last 4 months Presence of secondary infection requiring antibiotic treatment Pregnant or lactating mother Patients diagnosed with other type of kshudra kushta

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of Aaragwadhadi Kashay in reducing severity of Vicharchika (Atopic dermatitis) using EASI (Eczema Area and Severity Index) scaleTimepoint: Assessment on 0th 7th 14th 21th 28th and 60th day.	—

Secondary

Measure	Time frame
To assess the effect of Aaragwadhadi kashay in itching and sleep quality using DLQI (Dermatology Life Quality Index) To assess the association of IgE with disease activity and note changes if any occurs. To assess the tolerance of drug during treatment period To assess incidence and severity of relapse during post treatment drug free observation periodTimepoint: Assessment on 0th 7th 14th 21th 28th and 60th day.	—

Measure

Time frame

To assess the effect of Aaragwadhadi kashay in itching and sleep quality using DLQI (Dermatology Life Quality Index) To assess the association of IgE with disease activity and note changes if any occurs. To assess the tolerance of drug during treatment period To assess incidence and severity of relapse during post treatment drug free observation periodTimepoint: Assessment on 0th 7th 14th 21th 28th and 60th day.

—

Countries

India

Contacts

Public ContactDr Aparna N Sathe

Dr GD Pol Foundation YMT Ayurvedic Medical College

vdaparnasathe@gmail.com9819216230

Outcome results